Added Value of Baseline 18F-FDG Uptake in Serial 18F-FDG PET for Evaluation of Response of Solid Extracerebral Tumors to Systemic Cytotoxic Neoadjuvant Treatment: A Meta-Analysis
Open Access
- 16 September 2010
- journal article
- research article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 51 (10) , 1507-1516
Abstract
The purpose of this study was to test the hypothesis that the level of baseline 18F-FDG uptake in the primary tumor adds value to its relative change in 18F-FDG uptake in serial PET scans in predicting the histopathologic response to systemic cytotoxic neoadjuvant treatment of patients with solid extracerebral tumors. Methods: We performed a literature search from January 1995 through November 2008 using PubMed and Embase. Two reviewers independently selected eligible studies for possible inclusion in the meta-analysis by reviewing titles and abstracts. Inclusion criteria were at least 10 patients, 18F-FDG PET before and after therapy, 18F-FDG PET performed with the intention of monitoring the response of solid extracerebral tumors in humans to cytotoxic neoadjuvant systemic therapy, attenuation-corrected 18F-FDG PET studies, and studies presenting individual patient data (PET results and histopathologic reference test after treatment). Multilevel logistic regression was used to assess the effect of relative change of 18F-FDG uptake ([baseline – end]/baseline) and baseline 18F-FDG uptake value with type of tumor and type of treatment as level 1 covariates. Results: Nineteen studies (all observational; a total of 438 patients [median, 23 patients per study; range, 10–40]) were included, aiming at the accuracy of PET versus histopathology. To quantify PET, maximum standardized uptake value (SUV) was used in 6 studies, mean SUV in 7, SUV (subtype unclear) in 1, tumor-to-background ratio in 3, and dose uptake ratio in 1. The average overall histopathologic response rate was 0.47 (median, 0.50), ranging from 0.17 to 0.88. The relative change in 18F-FDG uptake was the strongest indicator (P < 0.0001) for tumor response. Baseline 18F-FDG was not significantly associated as a main factor; however, a significant interaction of baseline uptake and relative change after therapy was observed (P < 0.001). Conclusion: Relative change in 18F-FDG uptake was the strongest indicator for tumor response, but the level of baseline 18F-FDG uptake in the primary tumor provided additional information about prediction of response to therapy. These data corroborate and extend the need for standardization, quality assurance, and control of PET studies quantifying 18F-FDG in oncologic treatment monitoring.Keywords
This publication has 26 references indexed in Scilit:
- Combined Assessment of Metabolic and Volumetric Changes for Assessment of Tumor Response in Patients with Soft-Tissue SarcomasJournal of Nuclear Medicine, 2008
- Positron emission tomography and pathological evidence of response to neoadjuvant therapy in adenocarcinoma of the esophagusDiseases of the Esophagus, 2008
- Recommendations on the Use of 18F-FDG PET in OncologyJournal of Nuclear Medicine, 2008
- Primary Tumor Standardized Uptake Value (SUVmax) Measured on Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) is of Prognostic Value for Survival in Non-small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging ProjectJournal of Thoracic Oncology, 2008
- F-18 FDG PET and PET/CT Evaluation of Response to Chemotherapy in Bone and Soft Tissue SarcomasClinical Nuclear Medicine, 2008
- Appropriate Assessment of Neighborhood Effects on Individual Health: Integrating Random and Fixed Effects in Multilevel Logistic RegressionAmerican Journal of Epidemiology, 2005
- Combined use of MRI and PET to monitor response and assess residual disease for locally advanced breast cancer treated with neoadjuvant chemotherapy1Academic Radiology, 2004
- General SummaryMolecular Psychiatry, 2004
- Time Course of Tumor Metabolic Activity During Chemoradiotherapy of Esophageal Squamous Cell Carcinoma and Response to TreatmentJournal of Clinical Oncology, 2004
- Response of Osteosarcoma to Chemotherapy Evaluation with F-18 FDG-PET ScansClinical Positron Imaging, 2000